Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
New angiogenesis study findings have been reported by scientists at Radboud University
June 17th, 2009
"Vascular endothelial growth factor-A (VEGF-A) is one of the most important factors inducing angiogenesis in tumors. Nine splice-variant isoforms of VEGF-A have been identified, each having different properties," researchers in Netherlands report. "Recently, we showed that radiolabeled anti-VEGF monoclonal antibody, bevacizumab, accumulates specifically in VEGF-A expressing tumors. In this study, we investigated in a nude mouse model which VEGF-isoforms are responsible for tumor accretion. The humanized anti-VEGF-A antibody, A. 4.6.1. (bevacizumab), was radiolabeled with In-111. The originally VEGF-negative Me157 tumor was transfected with different VEGF isoforms...
Source: Immunotherapy Weekly (2009-06-17)
|
